APTO

$APTO chatter on StockTwits

• 
  Arman@Arman01BearishDec 1

  $APTO since 2015 i holding this garbage stock start buying by $7/share, then it's keep going down to less than $1 I had only one option to buy more & keep average down, then additionally they made reverse split multiple time to make my type of investor's investment up to $0 , approx 6 months ago they made again reverse split, now they saw lots of pipeline products & research will going to successful in near future so they planed to sell apto & cash out my type of all investor's investment with deep loss, they are big trapper or gamblers

  View on StockTwits ↗
• 
  Biotech Swingtrader@RadioIsotope25BullishNov 8

  $APTO

  View on StockTwits ↗
• 
  Tim The Enchanter@NatchoAug 25

  @Richardo8586 Story of my life too! I invested in ACXP pre-IPO, got screwed on the IPO, and now I'm down 95%. Don't get me started on $APTO, $KNW, etc. At least I kept a bunch of assets in conventional investments, so I'm going to be OK. But....hate KSS with a passion. Blowhard is being nice. He's a vindictive, petty, small minded troll.

  View on StockTwits ↗
• 
  Paulydestefano@paulydestefanoJul 18

  RSLS is the type of biotech play that goes vertical before most even react. You’ve got a confirmed merger, an ultra-low float, and a sub-$1 price tag. No dilution hanging over it, no crowd just structure, silence, and a trigger waiting to hit. These are the ones that gap up 100–300% in a blink. $CRIS $LITS $APTO $CTXR

  View on StockTwits ↗
• 
  hardrock@hardrock2112Jul 1

  $APTO APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company has been upgraded to list for trading on the OTCQB Market under the ticker “APTOF,” in addition to the Company’s continued listing on the Toronto Stock Exchange (TSX) under the symbol “APS”. Trading on OTCQB begins today, July 1, 2025 .

  View on StockTwits ↗
• 
  Bullseye@BullsEye2000BullishJun 18

  $APTO why would I do that? By then I would’ve already collected my 10-15% returns. Go look up the definition of day trading. Stop losses. They’re tools you can use to avoid getting wrecked on this stuff. Wild man, it’s wild that you don’t get it. This clown actually thinks I’m telling people to buy and hold this for life 😂

  View on StockTwits ↗
• 
  RiccoMercado@RiccoMercadoBullishJun 6

  SUPER RUN INCOMING ON GLMD 🚨 History repeats in small caps… and GLMD fits the mold. 📈 $SIGL — $0.10 to $4+ on float frenzy 📈 $HZNP — $2 to $120+ after biotech breakout 📈 $AQST — $0.70 to $8 on FDA hype 📈 $AMRX — under $1 to $6+ on revival spark 📈 $APTO — $0.30 to $10 on oncology buzz Now GLMD sits quietly… 🔹 Book value: $12 🔹 Cash rich 🔹 Tiny float 🔹 Massive upside potential Same setup. Same coiled spring. All it needs is a spark.

  View on StockTwits ↗
• 
  Mike@Redtrader101May 8

  $APTO anyone know if this will be trading again anytime soon?? Or how to sell.

  View on StockTwits ↗
• 
  :)@TCzeckBullishMay 6

  $APTO $NVNI $RLYB $HIND $WGHW $RLYB Get ready for tomorrow bulls. If the fire side chat returns great news, this will rise! I love hidden gems like this stock, no one is talking about it, shorts have low existence, highly owned percentage of institutions, insider purchases via form 4's SEC filings. Fingers crossed bulls! 🤞🏻

  View on StockTwits ↗
• 
  :)@TCzeckBullishMay 5

  $APTO $NVNI $RLYB $HIND $WGHW

  View on StockTwits ↗
• 
  :)@TCzeckMay 5

  $APTO $NVNI $RLYB $HIND $WGHW

  View on StockTwits ↗
• 
  :)@TCzeckBullishMay 5

  $RLYB Keep a huge eye out for 2 specific dates, May 7th and May 13th. May 7th is a fire side chat conference in NY. May 13th is a stockholder meeting involving critical company key points. $WGHW $HIND $NVNI $APTO

  View on StockTwits ↗
• 
  DonCorleone77@DonCorleone77May 5

  $APTO Aptose Biosciences reports data from Phase 1/2 TUSCANY trial Aptose Biosciences reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia patients dosed with a 40 mg or 80 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine. The TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Earlier this year, Aptose announced the initiation of the TUSCANY trial and dosing in newly diagnosed AML patients at an initial dose of 40 mg TUS in the first cohort of four patients. The second cohort of patients is now receiving 80 mg TUS. Data from the first two cohorts, with a 40 mg or 80 mg dose of tuspetinib in the TUS+VEN+AZA combination, reveal promising clinical safety and antileukemic activity. To date, four newly diagnosed AML patients received the initial dose of TUS as part of the combination. Notably, a patient with biallelic TP53 mutations and a complex karyotype and FLT3-wildtype achieved a complete remission (CR) and the clinical site reported no measurable residual disease in this patient. One FLT3-wildtype patient having an IDH-2 mutation achieved a CR and MRD-negative status. Another FLT3-wildtype patient achieved a CRi during Cycle 1 and MRD-negative status. The first three patients continue on treatment, while a fourth patient did not respond at this 40 mg dose level of TUS and was discontinued. The 40 mg dose of the TUS+VEN+AZA triplet remains safe, and no dose-limiting toxicities have been reported. To date, three newly diagnosed AML patients having diverse mutation profiles have received the 80 mg of TUS, as part of the TUS+VEN+AZA combination. The 80 mg TUS dose has been considered the optimal dose that has demonstrated safety and consistent blood exposure levels that exert potent antileukemic activity. All patients achieved blast reductions in Cycle 1 that met the criteria for complete remissions and continue on treatment. Notably, another TP53-mutated/CK and FLT3-wildtype patient achieved blast reductions that met CRi criteria in Cycle 1 and is now receiving additional therapy in Cycle 2. The second patient, having FLT3-wildtype status, achieved a CR. The third patient, having FLT3-ITD and NPM1 mutations and entering the trial with a 75% bone marrow blast count, achieved a CRi. All three patients are early in their course of treatment and are expected to show further improvements in their disease status as they are all continuing with treatment, and MRD status will be monitored as the patients move through their courses of therapy. The 80 mg dose of TUS, as part of the TUS+VEN+AZA triplet, continues to show favorable safety with no dose-limiting toxicities having been reported. "The treatment paradigm for AML is shifting to triplet combination therapy," said Rafael Bejar, CMO. "We have always maintained that tuspetinib, with its notable safety profile and ability to treat the larger, difficult-to-treat AML populations with high-risk mutations, could be an ideal drug for a triplet combination therapy in the frontline setting. With the majority of patients already achieving complete responses -- including early responses in patients with adverse mutations -- the clinical findings to date are bearing that out."

• 
  Δ@TheCodexDeltaBullishApr 11

  $APTO No LULD on the OTC...

  View on StockTwits ↗
• 
  Billy Peters@CantNameThatTuneApr 3

  $APTO help me to understand here. Last week TNON announced a huge FDA approval for their spinal fusion device to be used immediately worldwide. They did an offering so they could immediately begin commercializing the device. The offering came at two bucks and prices down at $1.40. from what I can see here APTO did an offering today just to keep the doors open and pay the rent with no FDA approvals. Why is this thing still up over $2 when the offering was $1.19?

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.